SEC Tracker
Get the app

Cardiff Oncology CRDF

Cardiff Oncology appoints interim CMO

Item 5.02 Executive or director change, Item 5.03 Amends charter or bylaws, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Dr. Roger Sidhu left as CMO on Oct 22, 2026
  2. Dr. Leila Alland appointed as interim CMO starting Oct 23, 2026
  3. Alland to be paid $35,000 monthly for 50% time
  4. Company increased common stock shares to 300M

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Cardiff Oncology files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Silence Therapeutics SLN public float $206M, Jun 30, 2025
  2. Rezolute RZLT public float $204M, Dec 31, 2025
  3. Tvardi Therapeutics TVRD public float $207M, Jun 30, 2025
  4. Natures Sunshine Products NATR public float $211M, Jun 30, 2025
  5. Rocket Pharmaceuticals RCKT public float $213M, Jun 30, 2025